These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28902567)

  • 1. Phase II cancer clinical trials for biomarker-guided treatments.
    Jung SH
    J Biopharm Stat; 2018; 28(2):256-263. PubMed ID: 28902567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analytical approach to assess the predictive value of biomarkers in Phase II decision making.
    Nikolakopoulos S; van der Wal WM; Roes KC
    J Biopharm Stat; 2013; 23(5):1106-23. PubMed ID: 23957519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 5. Biomarker enrichment considerations in oncology early development single-arm studies.
    Tian H; Liu K
    J Biopharm Stat; 2018; 28(2):282-291. PubMed ID: 28934023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues in oncology drug development, with a focus on Phase II trials.
    Sargent DJ; Taylor JM
    J Biopharm Stat; 2009; 19(3):556-62. PubMed ID: 19384696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.
    Ivanova A; Paul B; Marchenko O; Song G; Patel N; Moschos SJ
    J Biopharm Stat; 2016; 26(1):141-9. PubMed ID: 26368744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
    Seymour L; Ivy SP; Sargent D; Spriggs D; Baker L; Rubinstein L; Ratain MJ; Le Blanc M; Stewart D; Crowley J; Groshen S; Humphrey JS; West P; Berry D
    Clin Cancer Res; 2010 Mar; 16(6):1764-9. PubMed ID: 20215557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials.
    Englert S; Kieser M
    Stat Med; 2015 Jun; 34(13):2128-37. PubMed ID: 25781860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.
    Lin CJ; Wason JMS
    Stat Med; 2017 Dec; 36(29):4616-4626. PubMed ID: 28850689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of secondary endpoints in two-stage phase II oncology trials.
    Kunz CU; Kieser M
    Stat Med; 2012 Dec; 31(30):4352-68. PubMed ID: 22930470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Analysis of Cancer Clinical Trials for Personalized Medicine.
    Jung SH
    J Pers Med; 2021 May; 11(5):. PubMed ID: 34064394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.
    Goffin JR; Pond GR
    BMC Med Res Methodol; 2011 Dec; 11():164. PubMed ID: 22151297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting promising treatments in randomized Phase II cancer trials with an active control.
    Cheung YK
    J Biopharm Stat; 2009; 19(3):494-508. PubMed ID: 19384691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial design with growth modulation index as the primary endpoint.
    Wu J; Chen L; Wei J; Weiss H; Miller RW; Villano JL
    Pharm Stat; 2019 Mar; 18(2):212-222. PubMed ID: 30458583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flexible designs for phase II comparative clinical trials involving two response variables.
    Bersimis S; Sachlas A; Papaioannou T
    Stat Med; 2015 Jan; 34(2):197-214. PubMed ID: 25274584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.